newsfilter
← Latest News
GlobeNewswire·

INVO Fertility Reports First Quarter 2026 Results Reflecting Strong Revenue Growth, Expanded Fertility Clinic Platform, and Improved Capital Structure

  • INVO Fertility reported Q1 2026 revenue of $2,015,225, a 23% increase compared to $1,637,185 in Q1 2025.
  • Consolidated clinic revenue rose 22% to $1,982,233, driven by organic growth initiatives & the partial-quarter contribution from the Family Beginnings acquisition.
  • Net loss from continuing operations was $(5.5) million, which included a $3.8 million non-cash loss on warrant liability fair value changes prior to reclassification to equity.
  • Total net loss was $(5.5) million, a significant improvement from the $(17.4) million loss in Q1 2025 that included a $15.9 million loss from discontinued NAYA Therapeutics operations.
  • Adjusted EBITDA was $(1.26) million compared to $(0.6) million in the prior year, reflecting investments made to support future clinic expansion & growth.
  • The company eliminated all Series C-2 Preferred Stock & warrant liabilities, ending the quarter with $0 of each compared to $2.4 million & $1.9 million respectively at year-end 2025.
  • Stockholders' equity increased 108% to $15.0 million ($9.16 per share), while total liabilities decreased 26% to $9.6 million.
  • Cash balances improved to $4.9 million at March 31, 2026, up from $2.1 million at December 31, 2025.
  • The company received approximately $7.1 million in net proceeds from warrant exercises, used to satisfy deferred acquisition consideration & reduce debt.
  • As of June 22, 2026, there were 1,786,035 common shares outstanding, with a fully diluted share count of approximately 4.85 million.
  • The acquisition of Family Beginnings in February 2026 added a fourth operational fertility clinic, expanding the company's Midwest presence.
  • Management increased personnel in operations, human resources, & finance to support infrastructure required for further organic & acquisition growth.
  • The company now operates four fertility clinics in the U.S. while continuing INVOcell commercialization through third-party clinics.